Abstract:Background: Increased HBV-replication and/or intracellular HBsAgretention favor the onset of hepatocellular-carcinoma (HCC).Here, we define mutations in pre-S1/Pre-S2/S-gene correlated with HBVinduced HCC in-vivo, and investigate their impact on HBsAgretention and secretion in an in-vitro model.Methods: Sixty-seven HBV chronically-infected patients (74.6% genotype-D; 20.9% genotype-A; and 4.5% others), 19 of them with HCC and 48 asymptomatic patients (as control), were analyzed.Association of mutations with HCC was assessed by Fisher-test with Benjamini-Hochberg for multiple-comparison correction.Mutants were constructed by site-directed mutagenesis and expressed in HuH7-hepatocytes using the expression-vectors pCHD9 with fulllength HBV-genome (for mutations S98T S1 -P203Q S -S210R S ) and pCHsAgD with pre-S1/pre-S2/S-gene (for N40I S -K141N S ).After 72h quantitative-HBsAg was tested in cell-supernatants and in celllysates using Abbott-Architect assay.Results: Novel mutations in pre-S1 (S98T S1 ), and S region (N40I S -K141N S -P203Q S -S210R S ) correlate with HCC (P = 10 -2 to 10 -4 ) invivo.19/19 patients with HCC carry ≥1 of them (range-prevalence: 12.5% to 37.5%), while these mutations are absent (0/48 for N40I S ) or occurring with low frequency (1.9% for K141N S -P203Q S , 4.7% for S98T S1, 7.5% for S210R S ) in non-HCC patients.Strong correlations are observed for P203Q S +S210R S (phi=0.83)and N40I S +K141N S (phi=0.56).S98T S1 corresponds to the nucleotide codon 3175-3177 of HBVgenome localized in the promoter of the middle S-protein.In in-vitro experiments, its presence determines a 3.71 foldincrease in HBsAg-levels released in supernatants (S98T: 127.47[sd±53.45]IU/ml;WT: 34.40[sd±13.28]IU/ml,P = 0.00016).An opposite scenario is observed for P203Q S +S210R S , localized in the membrane-embedded C-terminal domain critical for HBsAg-secretion.This couple of mutations drastically decreases supernatant HBsAg-levels compared to P203Q and S210R alone, and to wild-type (P203Q+S210R: 9.42[sd±1.35]IU/ml;P203Q: 26.85[sd±13.01]IU/ml;S210R: 25.95[sd±8.82]IU/ml;WT: 34.40[sd:±13.28]IU/ml,P < 0.01).P203Q+S210R also decrease the ratio of supernatant to lysate HBsAg compared to wild-type (0.61 for P203Q+S210R versus 1.20 for wild-type), supporting their ability in inducing HBsAg intracellular-retention.Similarly, K141N determines a 52%-reduction of supernatant HBsAglevels compared to wild-type (K141N: 13.43[sd±9.68]IU/ml;WT: 28.25[sd±13.12]IU/ml.This reduction is greater when K141N is co-present with N40I (K141N+N40I: 4.67[sd±2.31]IU/ml,P = 0.012).K141N introduces a new N-linked glycosylation-site, while N40I resides in the cytosolic-loop involved in HBsAg-secretion.Conclusions: Key genetic-elements in pre-S1/pre-S2/S-gene correlate with HCC by inducing intracellular HBsAg-retention and/or by potentially altering the production of mRNAs for S-gene.Their detection may help identifying patients at higher HCC-risk.

PP-102 The study of the CD4+CD25+treg induced by human plasmacytoid dendritic cells from chronic hepatitis B in vitro

Detecting of the Hepatic Fibrotic Indexes and Serous Markers from Patients with Chronic Hepatitis B (chb)and Variation of HBV DNA YMDD

Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array

Study on the Immune Response Induced by Hbcag Gene-Modified Dendritic Cells in Hepatitis B Virus Transgenic Mice

Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs.

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Mutations in Precore and Core Promoter Region of HBV in Patients with Hepatic Failure.

Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

432 TRANSFER OF HEPATITIS B SURFACE MARKERS AND HBVDNA FROM HEPATITIS B SURFACE ANTIGEN POSITIVE MOTHERS TO THEIR OFFSPRING

Influence of C107R mutation from hepatitis B virus genotype H on in vitro hepatitis B surface antigen detection and IFN-β-1a treatment

Effects of Amino Acid Substitutions in Hepatitis B Virus Surface Protein on Virion Secretion, Antigenicity, HBsAg and Viral DNA.

The Modulation of HBsAg Level by Si126t is Affected by Additional Amino Acid Substitutions in the S Region of HBV.

Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B with HBsAg < 100 IU/ml

The Study on the Relationship Between Expression of B7-H1 on HBV Transgenic Mice and Immune Toler-Ance to HBV

Naturally Occurring Mutations Within Hbv Surface Promoter Ii Sequences Affect Transcription Activity, Hbsag And Hbv Dna Levels In Hbeag-Positive Chronic Hepatitis B Patients

Novel Assay of Competitively Differentiated Polymerase Chain Reaction for Screening Point Mutation of Hepatitis B Virus.

Effect of HBV G145R Mutation on the Antigenicity of S Protein and the Synthetic Peptide of "a" Determinant

Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients

Hepatitis B Virus Mutations Associated with in Situ Expression of Hepatitis B Core Antigen, Viral Load and Prognosis in Chronic Hepatitis B Patients